Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera

Simply Wall St.08-30

Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2663819042?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-30 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663819042","market":"sg","top_or_hot":-1,"title":"Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera","media":"Simply Wall St.","content":"<div>\n<p>Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-could-be-13-undervalued-on-fda-app\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-30 23:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-could-be-13-undervalued-on-fda-app><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-could-be-13-undervalued-on-fda-app\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154245756.USD","symbol_name":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-could-be-13-undervalued-on-fda-app","article_id":"2663819042","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/jazz-pharmaceuticals-jazz-could-be-13-undervalued-on-fda-app","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2663819042","pubTimestamp":1788103340,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by Phase 3 HERIZON GEA 01 data.\nJazz Pharmaceuticals’ recent FDA decision arrives after a strong run in the stock, with the share price up 41.23% year to date and a 1-year total shareholder return of 91.42%. This comes even though the 7-day share price return declined...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4588":"碎股","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","JAZZ":"爵士制药","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LABU":"三倍做多标普生物-Direxion","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"FDA 批准 Ziihera 后，Jazz Pharmaceuticals (JAZZ) 可能被低估 13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"JAZZ":1.5},"content_text":"Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by Phase 3 HERIZON GEA 01 data. Jazz Pharmaceuticals’ recent FDA decision arrives after a strong run in the stock, with the share price up 41.23% year to date and a 1-year total shareholder return of 91.42%. This comes even though the 7-day share price return declined 3.83% and short term momentum has eased slightly. Spot 19 high quality undiscovered gems that, similar to Jazz Pharmaceuticals after its Ziihera approval, pair focused drug portfolios with material late stage catalysts in under-followed corners of healthcare.\nAfter a 91.42% 1-year total return and Ziihera’s approval, Jazz Pharmaceuticals now sits at a very different share price and business mix. Is it more sensible to step in after this move, or to wait for a cheaper entry as the valuation settles? AdvertisementMost Popular Narrative: 13.1% Undervalued Against a last close of $244.54, the most followed narrative pegs Jazz Pharmaceuticals’ fair value at $281.35, framing the recent Ziihera approval inside a broader growth story built on oncology and neuroscience expansion.  Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands, which may position Jazz for steady long-term market share and revenue growth.  Read the complete narrative. Read the complete narrative. Want to see what sits behind that higher fair value for Jazz Pharmaceuticals? The narrative focuses on compounding revenue, rising margins, and a richer future earnings multiple. Curious which specific growth paths and profitability assumptions are used to support that upgrade over the current price? Result: Fair Value of $281.35 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Jazz Pharmaceuticals still faces real pressure if oxybate competition bites harder than expected, or if key oncology launches and trials hit regulatory or clinical setbacks. Find out about the key risks to this Jazz Pharmaceuticals narrative. Next Steps With Jazz Pharmaceuticals pulling in both concerns and optimism, it makes sense to move quickly and test the data yourself before opinions harden. To see how those red flags stack up against the upside potential, review the 3 key rewards and 2 important warning signs Looking for more investment ideas beyond Jazz Pharmaceuticals? Do not stop with Jazz Pharmaceuticals. Use the Simply Wall Street Screener to spot other opportunities that match your style before the crowd pays attention.  Target reliable compounding potential by scanning for consistent cash generation and valuation support through the 45 high quality undervalued stocks. Prioritize stability by focusing on companies with robust finances using the list of solid balance sheet and fundamentals (52 results). Hunt for early-stage opportunities with quality signals already in place via the 22 elite penny stocks with strong financials.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663819042","isCrawlerRequest":true}